L3VLUP
ProSign in

EW · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

EWLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • EW
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterEWLLY
Q3 202021 holders, $6.1bn33 holders, $14.1bn
Q4 202014 holders, $6.3bn29 holders, $17.3bn
Q1 202122 holders, $6.0bn24 holders, $23.0bn
Q2 202125 holders, $7.7bn24 holders, $27.8bn
Q3 202122 holders, $8.5bn31 holders, $29.9bn
Q4 202120 holders, $9.2bn31 holders, $34.7bn
Q1 202222 holders, $7.9bn24 holders, $35.3bn
Q2 202222 holders, $6.6bn33 holders, $42.7bn
Q3 202229 holders, $6.2bn31 holders, $43.4bn
Q4 202228 holders, $5.8bn31 holders, $46.6bn
Q1 202326 holders, $5.8bn33 holders, $44.3bn
Q2 202325 holders, $5.9bn37 holders, $59.6bn
Q3 202325 holders, $4.6bn44 holders, $67.6bn
Q4 202322 holders, $5.1bn45 holders, $73.6bn
Q1 202423 holders, $7.0bn41 holders, $95.3bn
Q2 202420 holders, $6.8bn43 holders, $110bn
Q3 202419 holders, $3.8bn45 holders, $107bn
Q4 202422 holders, $5.0bn46 holders, $93.9bn
Q1 202523 holders, $5.0bn42 holders, $98.4bn
Q2 202523 holders, $5.2bn43 holders, $93.2bn
Q3 202522 holders, $5.0bn39 holders, $86.7bn
Q4 202523 holders, $5.9bn41 holders, $123bn
Q1 202625 holders, $6.0bn39 holders, $106bn
Q2 202625 holders, $6.9bn44 holders, $132bn
EW

Edwards Lifesciences Corp

Holders
22
Reported value
$5.0bn
Buyers
9
Sellers
15

Breadth -6 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
39
Reported value
$86.7bn
Buyers
22
Sellers
22

Breadth 0 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 42 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only EW (3)

Baillie Gifford & Co, Point72 Asset Management LP, Viking Global Investors LP

Only LLY (20)

Arrowstreet Capital LP, Artisan Partners LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Invesco Ltd, Jane Street Group LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →